Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.62 |
| ▸ | GABRD | O14764 | 2/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.62 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.62 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.62 |
| ▸ | GABRE | P78334 | 2/20 | 0.62 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.62 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.62 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.62 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25309194 | 0.85 | GABRP (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3123429 | 0.83 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1874529 | 0.83 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17097356 | 0.81 | KEAP1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Bromide SCHEMBL4662721 | 0.81 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14143222 | 0.81 | MAPT (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4595837 | 0.80 | GABRP (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16797558 | 0.79 | ALDH1A1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29919922 | 0.79 | ALDH1A1 (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6219254 | 0.78 | GABRP (0.65) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118647270-A | Novel derivatives of non-coding amino acids and their use as herbicides | 福提费斯特有限公司 | 2024-09-13 | — | — | CN | claimed |
| WO-2023131951-A1 | NOVEL DERIVATIVES OF NON-CODED AMINO ACIDS AND THEIR USE AS HERBICIDES | FORTEPHEST LTD. (IL) | 2023-07-13 | — | — | WO | claimed |
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4556466-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025082316-A1 | OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州必扬医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085554-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085564-A1 | LYSINE ACETYLTRANSFERASE INHIBITORS | Kronos Bio, Inc. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-112739695-B | Novel thiazole derivative and pharmaceutically acceptable salt thereof | 永进药品工业株式会社 | 2025-03-18 | — | — | CN | disclosed |
| CN-119604488-A | Protein tyrosine kinase inhibitor and medical application thereof | 苏州必扬医药科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | YUNGJIN PHARM. CO., LTD. (KR) | 2024-10-08 | — | — | US | disclosed |
| CN-118647270-A | Novel derivatives of non-coding amino acids and their use as herbicides | 福提费斯特有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | BISHOP W ROBERT (US) | 2002-06-06 | — | — | US | disclosed |
| US-6365588-B1 | AS ANTINEOPLASTIC AGENT AND A POTENTIATING | SCHERING CORPORATION | 2002-04-02 | — | — | US | disclosed |
| US-6242458-B1 | INHIBITING FARNESYL PROTEIN TRANSFERASE IN A HUMAN | SCHERING CORPORATION | 2001-06-05 | — | — | US | disclosed |
| US-5807853-A | Tricyclic amide and urea compounds, useful inhibition of g-protein function and for treatment of proliferative diseases | SCHERING CORPORATION (US) | 1998-09-15 | — | — | US | disclosed |
| US-5719148-A | FARNESYL-PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5714609-A | FORMING CHEMICAL INTERMEDIATE BY NITRATING SUBSTITUTED BENZO/5,6/CYCLOHEPTA/1,2-B/PYRIDINE WITH TETRABUTYLAMMONIUM NITRATE AND TRIFLUOROACETIC ANHYDRIDE IN SOLVENT AT REDUCED TEMPERATURE | SCHERING CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0815100-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5696121-A | 4-(3-BROMO 8-CHLORO-6,11-DIHYDRO-5H-BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE-11-YL)-N-(3 -PYRIDINYL)-1-PIPERAZINECARBOXIDE; ANTITUMOR AGENT; FARNESYL PROTEIN TRANSFERASE INHIBITOR | SCHERING CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1996030363-A1 | TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES | SCHERING CORPORATION (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110299-B2 | Thiazole derivatives and pharmaceutically acceptable salts thereof | CDKL1, CDK4, CDKL3 | GABRP 4427/4885GABRD 4102/4885GABRA1 4363/4885 |
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | KDR, FLT1, ERBB2 | GABRP 3106/4885GABRD 4311/4885GABRA1 3733/4885 |
| US-20020068742-A1 | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | RASGRP1, CCNA1, CCNA2 | GABRP 2257/4885GABRD 3346/4885GABRA1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.